COMPASS Pathways plc
CMPS$13.54
$-0.01 (-0.07%)-0.07%
ClosedLoading chart...
IndexN/A
Market Cap1.83B
Enterprise Value0.52B
Income$-0.02B
Sales$0.00B
EmployeesN/A
P/E-4.30
P/S0.00
P/B-12.21
P/C-4.10
EV/EBITDA-1.81
EV/SalesN/A
EPS (ttm)-3.15
EarningsN/A
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Volume3.39M
Shs Outstand0.13B
Change-0.07%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $112.87K | $63.00K | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $-112.87K | $-63.00K | $0.00 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Expenses | $178.21M | $136.92M | $110.40M | $83.22M | $51.68M | $21.12M | $12.50M |
| Operating Income | $-178.21M | $-136.92M | $-110.40M | $-83.22M | $-51.79M | $-21.18M | $-12.50M |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | $-155.12M | $-118.46M | $-91.50M | $-71.74M | $-60.80M | $-19.61M | $-13.22M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS (Basic) | $-2.30 | $-2.32 | $-2.16 | $-1.79 | $-1.68 | $-0.90 | $-2.35 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $213.67M | $275.99M | $197.29M | $300.90M | $203.46M | $32.39M | $26.39M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $58.97M | $50.24M | $16.01M | $16.49M | $6.89M | $23.87M | $40.75M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $154.69M | $225.74M | $181.28M | $284.41M | $196.56M | $8.52M | $-14.37M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $154.69M | $225.74M | $181.28M | $284.41M | $196.56M | $8.52M | $-14.37M |
| Total Liabilities & Stockholders Equity | $213.67M | $275.99M | $197.29M | $300.90M | $203.46M | $32.39M | $26.39M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|
| Net Income | $-155.12M | $-118.46M | $-91.50M | $-71.74M | $-60.80M | $-19.61M | $-13.22M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-119.19M | $-97.38M | $-105.45M | $-67.75M | $-41.38M | $-17.81M | $-9.80M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Compass Pathways to Participate in Canaccord Genuity's 46th Annual Growth Conference on August 12, 2026businesswire.com Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybinbusinesswire.com Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com COMPASS Pathways plc (CMPS) Q2 2026 Earnings Call Transcriptseekingalpha.com Compass Pathways Q2 Earnings Call Highlightsmarketbeat.com Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlightsbusinesswire.com Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026businesswire.com Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.fool.com
Show 12 more stories
Compass Pathways: The Psilocybin Biotech Leader With Strong Momentumseekingalpha.com Compass Pathways (CMPS) to Post Quarterly Earnings on Thursdaydefenseworld.net Compass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapyproactiveinvestors.com Compass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapyproactiveinvestors.com Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapybusinesswire.com Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferiesproactiveinvestors.com CleanSpark shares surge after company secures $6.6B data center lease agreementproactiveinvestors.com Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capacityproactiveinvestors.com Compass Pathways Eyes 2027 Launch as Psilocybin Depression Data Holds Upmarketbeat.com Compass Pathways: 'Strong Buy' COMP360 Trial Wins And Q4 NDA Full Submissionseekingalpha.com COMPASS Pathways plc (CMPS) Discusses Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile in Depression Transcriptseekingalpha.com Compass Pathways Highlights Long-Term Data from Resistant Depression, Backs 2027 Launch Timelinebenzinga.com
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Discover more
You may be interested in